At Karius, we are committed to diagnostic stewardship, which means supporting you in identifying the right patient, right test, and right time to use Karius testing solutions.
Karius is a clinical metagenomics company focused on helping elevate patient care through microbial insights. We are a team of infectious disease experts, including medical directors and medical science liaisons who are committed to patients, research and advancing diagnostic science.
Karius helps healthcare providers detect pathogens by leveraging microbial cell-free DNA (mcfDNA). As microbes turn over, they shed genomic fragments in the body, leaving behind traces that hold critical clinical insights. Using metagenomic sequencing and artificial intelligence, we identify, analyze, and report these signals.
Karius Spectrum is a blood test based on metagenomic sequencing of plasma microbial cell-free DNA that can detect over 1,000 pathogens associated with deep-seated and difficult-to-diagnose systemic infections caused by fungi, bacteria, parasites, and DNA viruses.
The main clinical application for our testing solutions is to help detect infections in both immunocompromised and immunocompetent patients.
ASTCT Guideline Highlights the Karius Spectrum test for infection diagnosis in patients who have undergone hematopoietic stem cell transplantation.
View PublicationPer consensus guidance sponsored by American Society of Transplantation: Plasma-based NGS may be useful when a focal site of infection cannot be accessed for sampling.
View PublicationFirst time inclusion of hypothesis-free metagenomic testing, such as the Karius Spectrum test for the rapid identification of hard-to-detect pathogens.
View Publication
